



**Supplemental Figure S7: Benchmarking antigen presentation by TR-APCs.** **A-B**, Frequencies of DC populations in the inguinal lymph node (**A**) or spleen (**B**) of BALB/c-Langerin-DTR<sup>+/−</sup> Ptprc<sup>a/b</sup> mice following vehicle treatment or DT-mediated depletion. Plots shown as a frequency

of live CD11c<sup>+</sup>I-A/I-E<sup>+</sup> events. **C**, Histogram of MHC-I expression in RAW-112 cell (black) and RAW-112 TAP-1 knockout (red) cells. **D**, Purification strategy for FACS sorting of DC: RAW-112 fusion cells following PEG-mediated cell fusion. **E**, T cell activation of BALB/c CD4<sup>+</sup> and CD8<sup>+</sup> T cells co-cultured with RAW-112 TR-APCs or DC: RAW-112 fusion cells. **F**, Kaplan-Meier curve showing survival of BALB/c mice vaccinated with *ex vivo* generated RAW-112 TR-APCs, DC: RAW-112 fusion cells, vaccinated *in situ* with RAW-112 TR-APCs, or left unvaccinated.